We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Top Analyst Reports for Bristol-Myers, ConocoPhillips & Qualcomm
Read MoreHide Full Article
Monday, February 11, 2019
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Bristol-Myers (BMY - Free Report) , ConocoPhillips (COP - Free Report) and Qualcomm (QCOM - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Buy-ranked Bristol-Myers’ shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the past six months, -15.5% vs. +2.1%. Bristol-Myers topped fourth-quarter earnings on robust sales of Opdivo and Eliquis. Bristol-Myers' blockbuster immuno-oncology drug
The Zacks analyst thinks Opdivo’s performance is being boosted by the uptake in new indications in the United States - first line RCC and adjuvant melanoma. Eliquis is expected to drive growth, owing to increases in market share in the novel oral anticoagulant market. The label expansion of other drugs like Sprycel and Empliciti should further boost sales.
The recently announced acquisition of Celgene should strengthen the oncology franchise. However, the company’s voluntary withdrawal of the sBLA seeking approval of Opdivo+Yervoy as a treatment for first-line NSCLC with tumor mutational burden greater or equal to 10 mutations/megabase following discussions with the FDA was disappointing given the market potential.
Shares of ConocoPhillips are up 24% over the past year, outperforming the Zacks U.S. Integrated Oil industry, which has increased +0.1% over the same period. The Zacks analyst emphasizes that in terms of production and proved reserves, ConocoPhillips is the largest oil and gas exploration and production (E&P) player in the world.
Notably, there are significant opportunities for the upstream energy player in the Eagle Ford where it owns about 3,400 undrilled locations. In fact, strong focus on two other prospective resources like Delaware basin and Bakken shale is expected to help ConocoPhillips achieve its target of more than 25% CAGR of production through 2017 to 2019.
The company recently reported strong fourth-quarter 2018 earnings, thanks to robust volumes from the unconventional assets. However, the firm’s projection of higher production and operating costs is likely to hurt its bottom line. Moreover, since majority of ConocoPhillips’ production comprises oil, the volatile crude pricing scenario could hurt the company’s operations.
Qualcomm’s shares have lost 23.4% over the past year, underperforming the Zacks Wireless Equipment industry, which has lost -5.4% over the same period. Qualcomm reported mixed first-quarter fiscal 2019 results wherein the bottom line beat expectations but the top line missed the same. The company expects improving conditions for its chip business in the second half of fiscal 2019 on the back of new product launches.
The Zacks analyst likes how the company continues to execute its strategic objectives, including driving the global transition to 5G, protecting its intellectual property rights and expanding into new industries and product categories to stoke growth. Qualcomm’s Snapdragon 855 is gaining significant momentum with more than 100 design wins in development.
Aggressive competition in the mobile phone chipset market is likely to hurt profitability. Over the past quarters, Qualcomm’s results were adversely impacted by ongoing legal disputes with Apple. It is also facing competitive threat from its closest rival, Intel.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trendsand Earnings Previewreports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Top Analyst Reports for Bristol-Myers, ConocoPhillips & Qualcomm
Monday, February 11, 2019
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Bristol-Myers (BMY - Free Report) , ConocoPhillips (COP - Free Report) and Qualcomm (QCOM - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Buy-ranked Bristol-Myers’ shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the past six months, -15.5% vs. +2.1%. Bristol-Myers topped fourth-quarter earnings on robust sales of Opdivo and Eliquis. Bristol-Myers' blockbuster immuno-oncology drug
The Zacks analyst thinks Opdivo’s performance is being boosted by the uptake in new indications in the United States - first line RCC and adjuvant melanoma. Eliquis is expected to drive growth, owing to increases in market share in the novel oral anticoagulant market. The label expansion of other drugs like Sprycel and Empliciti should further boost sales.
The recently announced acquisition of Celgene should strengthen the oncology franchise. However, the company’s voluntary withdrawal of the sBLA seeking approval of Opdivo+Yervoy as a treatment for first-line NSCLC with tumor mutational burden greater or equal to 10 mutations/megabase following discussions with the FDA was disappointing given the market potential.
(You can read the full research report on Bristol-Myers here >>>).
Shares of ConocoPhillips are up 24% over the past year, outperforming the Zacks U.S. Integrated Oil industry, which has increased +0.1% over the same period. The Zacks analyst emphasizes that in terms of production and proved reserves, ConocoPhillips is the largest oil and gas exploration and production (E&P) player in the world.
Notably, there are significant opportunities for the upstream energy player in the Eagle Ford where it owns about 3,400 undrilled locations. In fact, strong focus on two other prospective resources like Delaware basin and Bakken shale is expected to help ConocoPhillips achieve its target of more than 25% CAGR of production through 2017 to 2019.
The company recently reported strong fourth-quarter 2018 earnings, thanks to robust volumes from the unconventional assets. However, the firm’s projection of higher production and operating costs is likely to hurt its bottom line. Moreover, since majority of ConocoPhillips’ production comprises oil, the volatile crude pricing scenario could hurt the company’s operations.
(You can read the full research report on ConocoPhillips here >>>).
Qualcomm’s shares have lost 23.4% over the past year, underperforming the Zacks Wireless Equipment industry, which has lost -5.4% over the same period. Qualcomm reported mixed first-quarter fiscal 2019 results wherein the bottom line beat expectations but the top line missed the same. The company expects improving conditions for its chip business in the second half of fiscal 2019 on the back of new product launches.
The Zacks analyst likes how the company continues to execute its strategic objectives, including driving the global transition to 5G, protecting its intellectual property rights and expanding into new industries and product categories to stoke growth. Qualcomm’s Snapdragon 855 is gaining significant momentum with more than 100 design wins in development.
Aggressive competition in the mobile phone chipset market is likely to hurt profitability. Over the past quarters, Qualcomm’s results were adversely impacted by ongoing legal disputes with Apple. It is also facing competitive threat from its closest rival, Intel.
(You can read the full research report on Qualcomm here >>>).
Other noteworthy reports we are featuring today include T-Mobile (TMUS - Free Report) , General Motors (GM - Free Report) and Marathon Petroleum (MPC - Free Report) .
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”
Click to get it free >>
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>